Study to Evaluate the Safety, Tolerability, and Efficacy of PEP-TISSEEL in Subjects With Chronic Radiation Ulcer
Phase 1
Not yet recruiting
- Conditions
- Chronic Radiation Ulcer
- Interventions
- Combination Product: PEP-TISSEELDrug: TISSEEL Fibrin Sealant KIT
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Rion Inc.
- Target Recruit Count
- 184
- Registration Number
- NCT06793748
- Locations
- 🇺🇸
Walter Reed National Military Medical Center, Bethesda, Maryland, United States
Phase 1b Clinical Trial to Evaluate PEP and EUFLEXXA for Knee Osteoarthritis (KOA)
Phase 1
Not yet recruiting
- Conditions
- Knee Osteoarthritis
- Interventions
- Combination Product: PEP/Euflexxa
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Rion Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06463132
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Phase 2a Multi-Center Prospective, Randomized Trial to Evaluate the Safety & Efficacy of Topical PEP-TISSEEL for Diabetic Foot Ulcers (DFU)
Phase 2
Recruiting
- Conditions
- Diabetic Foot Ulcer
- Interventions
- Biological: PEP (Purified Exosome Product) / TISSEEL
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Rion Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06319287
- Locations
- 🇺🇸
Professional Education & Research Institute (PERI), Blue Ash, Ohio, United States
PEP on a Skin Graft Donor Site Wound
Phase 1
Active, not recruiting
- Conditions
- Skin Graft
- Interventions
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Rion Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT04664738
- Locations
- 🇺🇸
International Research Partners, Doral, Florida, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
© Copyright 2025. All Rights Reserved by MedPath